HomeCompareORINY vs BTI

ORINY vs BTI: Dividend Comparison 2026

ORINY yields 2.66% · BTI yields 5.40%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $17.6K in total portfolio value
10 years
ORINY
ORINY
● Live price
2.66%
Share price
$37.99
Annual div
$1.01
5Y div CAGR
-45.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.2K
Annual income
$0.66
Full ORINY calculator →
BTI
BTI
● Live price
5.40%
Share price
$58.26
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.8K
Annual income
$2,802.29
Full BTI calculator →

Portfolio growth — ORINY vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodORINYBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ORINY + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ORINY pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ORINY
Annual income on $10K today (after 15% tax)
$226.00/yr
After 10yr DRIP, annual income (after tax)
$0.56/yr
BTI
Annual income on $10K today (after 15% tax)
$459.05/yr
After 10yr DRIP, annual income (after tax)
$2,381.95/yr
At 15% tax rate, BTI beats the other by $2,381.39/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ORINY + BTI for your $10,000?

ORINY: 50%BTI: 50%
100% BTI50/50100% ORINY
Portfolio after 10yr
$29.0K
Annual income
$1,401.47/yr
Blended yield
4.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

ORINY
Analyst Ratings
2
Buy
1
Hold
Consensus: Buy
Altman Z
18.6
Piotroski
6/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.3% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ORINY buys
0
BTI buys
0
No recent congressional trades found for ORINY or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricORINYBTI
Forward yield2.66%5.40%
Annual dividend / share$1.01$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-45.3%11.3%
Portfolio after 10y$20.2K$37.8K
Annual income after 10y$0.66$2,802.29
Total dividends collected$324.00$14.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusBuyBuy

Year-by-year: ORINY vs BTI ($10,000, DRIP)

YearORINY PortfolioORINY Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$10,845$145.43$11,301$601.08$456.00BTI
2$11,685$80.63$12,799$706.58$1.1KBTI
3$12,548$44.41$14,527$832.38$2.0KBTI
4$13,450$24.38$16,527$982.75$3.1KBTI
5$14,405$13.36$18,846$1,162.95$4.4KBTI
6$15,421$7.31$21,545$1,379.49$6.1KBTI
7$16,504$4.00$24,694$1,640.41$8.2KBTI
8$17,662$2.19$28,378$1,955.69$10.7KBTI
9$18,899$1.20$32,702$2,337.79$13.8KBTI
10$20,223$0.66$37,794$2,802.29$17.6KBTI

ORINY vs BTI: Complete Analysis 2026

ORINYStock

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, other European countries, North America, and internationally. It provides prescription drugs and self-care products, including Nubeqa for the treatment of prostate cancer; dexdor and Precedex for intensive care sedative; Stalevo and Comtess/Comtan for Parkinson's disease; Simdax for acute decompensated heart failure; and Fareston for breast cancer, as well as Salmeterol/fluticasone Easyhaler, Budesonide/formoterol Easyhaler, Formoterol Easyhaler, Budesonide Easyhaler, Beclomet Easyhaler, and Buventol Easyhaler drugs for the treatment of asthma and chronic obstructive pulmonary disease. The company also offers veterinary drugs comprising Bonqat, Clevor, Domosedan, Domitor, Antisedan, Dexdomitor, Domosedan Gel, Sileo, and Tessie; and APIs for generic and proprietary drugs, as well as provides contract manufacturing services. In addition, it markets and sells veterinary drugs manufactured by other international companies. The company serves various healthcare service providers and professionals, such as specialist and general practitioners, veterinarians, pharmacies, hospitals, healthcare centers, clinics, and laboratories, as well as consumers with pets. Orion Oyj has partnership with Propeller Health to connect the Easyhaler(R) product portfolio for the treatment of asthma and COPD; and a research collaboration and license agreement with Alligator Bioscience AB (publ) to discover and develop new bispecific antibody cancer therapeutics. Orion Oyj was founded in 1917 and is headquartered in Espoo, Finland.

Full ORINY Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this ORINY vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ORINY vs SCHDORINY vs JEPIORINY vs OORINY vs KOORINY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.